ProMIS Neurosciences Provides Third Quarter Update for 2017
(Thomson Reuters ONE) -
Updated corporate overview available on ProMIS website
TORONTO and CAMBRIDGE, Mass., Oct. 11, 2017 (GLOBE NEWSWIRE) -- ProMIS
Neurosciences, Inc., a biotechnology company focused on the discovery and
development of precision treatments for neurodegenerative diseases, today
provided a corporate update for the third quarter of 2017, including key
accomplishments and a status update on ongoing programs.
A narrated corporate overview of third quarter 2017 progress is available on the
ProMIS Neurosciences website at: http://bit.ly/2xuss6Q
Key accomplishments in the third quarter of 2017 and near-term value drivers
include:
* Closed second and final tranche of private placement, raising aggregate
gross proceeds of approximately CDN $4,800,000
* Successful humanization of lead product candidate PMN310 for Alzheimer's
disease
* PMN310 on track for 2019 initiation of clinical trials
* Expansion of potential best in class portfolio selectively targeting toxic
Amyloid beta oligomers (ABO) for Alzheimer's disease
* Designated PMN330 as third validated lead product candidate
demonstrating in vivo data and biologic evidence of neuronal protection
against toxic ABO
* Initiated humanization of PMN330 and PMN350
* Preclinical program initiated to confirm best in class profile of PMN310,
PMN350 and PMN330 in direct comparison to other antibodies targeting amyloid
beta
* Cohort study progress
* Technology refinement and optimization ongoing to create highly
sensitive assays for detection of ABO targets in cerebrospinal fluid
(CSF)
* Recognition and visibility at major international meetings
* Oral presentation and session chair at Alzheimer's Association
International Conference, London, UK, July, 2017
* Oral presentation at Third Annual R&D Technologies Conference, London,
UK, September, 2017
* Progress relating to multiple neurodegenerative diseases
* Generated monoclonal antibodies against a recently identified epitope
target on TDP43 for ALS and frontotemporal dementia and initiated
preclinical evaluation.
* Ongoing work using ProMIS proprietary discovery platform to identify
specific targets on alpha synuclein (Parkinson's disease and Lewy body
dementia) and tau (Alzheimer's disease, other dementias)
Commenting on the update, ProMIS Executive Chairman Eugene Williams stated: "Our
Alzheimer's disease program continues to make significant progress. With respect
to drug development, our priorities for this program are twofold: to drive
PMN310 to clinical trial initiation in 2019 and importantly, to further
differentiate our Alzheimer's product candidates as best in class in direct
comparison to other antibody treatments targeting Amyloid beta. With respect to
our research programs, we are pleased with the progress made using our
proprietary discovery engine to identify novel targets for multiple
neurodegenerative diseases."
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a Toronto Stock Exchange listed biotech company (trading
symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge,
Massachusetts. The Company's mission is to discover and develop precision
medicine therapeutics for effective treatment of neurodegenerative diseases, in
particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of
two, complementary techniques. The Company applies its thermodynamic,
computational discovery platform-ProMIS((TM)) and Collective Coordinates - to
predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular
surface of misfolded proteins. Using this unique "precision medicine" approach,
ProMIS Neurosciences is developing novel antibody therapeutics and specific
companion diagnostics for Alzheimer's disease and ALS.
The TSX has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release. This information release may contain certain forward-
looking information. Such information involves known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by statements herein,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on the
Company's current beliefs as well as assumptions made by and information
currently available to it as well as other factors. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. Due to risks and uncertainties, including the
risks and uncertainties identified by the Company in its public securities
filings, actual events may differ materially from current expectations. The
Company disclaims any intention or obligation to update or revise any forward-
looking statements, whether as a result of new information, future events or
otherwise.
For further information please consult the Company's website at:
www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
For media inquiries, please contact:
Scott Santiamo
RussoPartners/LLC
Scott.Santiamo(at)russopartnersllc.com
Tel. 718 344-5843
David Schull
RussoPartners/LLC
David.Schull(at)russopartnersllc.com
Tel. 858 717-2310
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick(at)alpineequityadv.com
Tel. 617 901-0785
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Elliot.goldstein(at)promisneurosciences.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Following Encouraging Drill Results, U.S. Gold Corp. Plans Additional Autumn Drill Program on the Keystone Project in Nevada
Datum: 11.10.2017 - 13:30 Uhr
Sprache: Deutsch
News-ID 563277
Anzahl Zeichen: 6988
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 225 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ProMIS Neurosciences Provides Third Quarter Update for 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
ProMIS Neurosciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
